Modality
Cell Therapy
MOA
TROP-2 ADC
Target
MALT1
Pathway
PI3K/AKT
EoE
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ Nov 2027
Phase 1Current
NCT08413050
1,111 pts·EoE
2024-04→2027-11·Not yet recruiting
NCT06989423
1,265 pts·EoE
2024-09→TBD·Terminated
2,376 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-151.6y awayPh2 Data· EoE
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
Ph2 Data
2027-11-15 · 1.6y away
EoE
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08413050 | Phase 1/2 | EoE | Not yet recr... | 1111 | Biomarker |
| NCT06989423 | Phase 1/2 | EoE | Terminated | 1265 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |